Get the Stockscreener App
65.08
0.84%
-0.55
After Hours:
65.08
Insmed Inc stock is traded at $65.08, with a volume of 2.39M.
It is down -0.84% in the last 24 hours and down -3.66% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$65.63
Open:
$65.63
24h Volume:
2.39M
Relative Volume:
1.15
Market Cap:
$13.15B
Revenue:
$342.96M
Net Income/Loss:
$-864.29M
P/E Ratio:
-11.73
EPS:
-5.55
Net Cash Flow:
$-636.03M
1W Performance:
-9.99%
1M Performance:
-3.66%
6M Performance:
-11.50%
1Y Performance:
+146.70%
1-Day Range:
$64.95
$66.91
1-Week Range:
$63.81
$72.83
52-Week Range:
$21.92
$84.91
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
65.08 | 13.15B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | I - GuruFocus
UBS Maintains Buy Rating, Lowers Price Target for Insmed (INSM) - GuruFocus
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates - Nasdaq
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
Is Insmed Incorporated (INSM) the Best Cancer Stock to Invest in for Long-Term Gain? - Insider Monkey
Insmed (INSM) Receives Slight Price Target Adjustment by UBS | INSM Stock News - GuruFocus
RBC Trims Price Target on Insmed to $99 From $100, Keeps Outperform Rating - marketscreener.com
Insmed: Q1 Earnings Snapshot - Greenwich Time
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed’s Earnings Call: Strong Growth and Optimistic Outlook - TipRanks
Insmed Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Insmed Incorporated, Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Earnings call transcript: Insmed Q1 2025 shows mixed results with slight EPS miss - Investing.com
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Insmed Q1 Net Loss Widens, Revenue Increases; 2025 Revenue Guidance Maintained - marketscreener.com
Insmed (INSM) Reports Q1 Revenue Surpassing Expectations and Awaits Key Approvals | INSM Stock News - GuruFocus
Insmed Q1 2025 slides: ARIKAYCE sales surge 23% as brensocatib launch approaches - Investing.com
Insmed earnings missed by $0.07, revenue topped estimates - Investing.com
Insmed Inc (INSM) Q1 2025 Earnings: Revenue Hits $92.8 Million, Surpassing Estimates - GuruFocus
Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update | INSM Stock News - GuruFocus
Insmed Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Dimensional Fund Advisors LP Sells 16,313 Shares of Insmed Incorporated (NASDAQ:INSM) - Defense World
Insmed Incorporated (INSM): Among the Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy - Insider Monkey
Earnings Preview: Insmed (INSM) Q1 Earnings Expected to Decline - Yahoo Finance
Insmed Incorporated (INSM): Among Billionaire George Soros’ Mid-Cap Stocks With Huge Upside Potential - Insider Monkey
Insmed To Present at the BofA Securities 2025 Health Care Conference - GuruFocus
Insmed To Present at the BofA Securities 2025 Health Care Conference | INSM Stock News - GuruFocus
Insmed Inc (INSM)’s Day in Review: Closing at 69.69, Up by 1.06 - DWinneX
Gaining Ground: Insmed Inc (INSM) Closes Lower at 72.00, Down -5.62 - DWinneX
Top Medical Stocks To Watch Now – April 25th - Defense World
Insmed Inc [INSM] moved down -2.60: Why It’s Important - dbtnews.com
Could investigational drug become first-in-class bronchiectasis therapy? - marketscreener.com
Insmed: Poised For Transformation Beyond ARIKAYCE (NASDAQ:INSM) - Seeking Alpha
Insmed Inc [INSM] stock for 479,177 USD was sold by Lewis William - knoxdaily.com
Insmed’s (INSM) Buy Rating Reiterated at HC Wainwright - Defense World
Insmed Sees Unusually Large Options Volume (NASDAQ:INSM) - Defense World
Insmed Inc (INSM) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Insmed Calls In Convertible Notes, Proposes Share Conversion - Finimize
Insmed to redeem $569.5 million convertible notes due 2028 By Investing.com - Investing.com Canada
Insmed Inc (NASDAQ:INSM) Rises 5.71% In 2025; Is It Still Attractive At $70.85? - Marketing Sentinel
INSM’s price-to-sales ratio: A comparative analysis with its peers - uspostnews.com
Insmed to Redeem $569.5 Million of Convertible Senior Notes - marketscreener.com
Insmed Announces Redemption of all $569.5 Million of Remaining O - GuruFocus
Insmed Flexes Financial Muscle with $569M Early Note Redemption: What it Means for Investors - Stock Titan
Insmed Incorporated (INSM): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Insmed (INSM) Reports Promising Phase 3 Results for Brensocatib - GuruFocus
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis | INSM Stock News - GuruFocus
Insmed (INSM) Reports Promising Phase 3 Results for Brensocatib in Treating Bronchiectasis | INSM Stock News - GuruFocus
New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis - marketscreener.com
Insmed to Host First-Quarter 2025 Financial Results Conference C - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lewis William | Chair and CEO |
May 01 '25 |
Sale |
72.57 |
6,830 |
495,668 |
233,924 |
0.31%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):